Eli Lilly And Co (NYSE:LLY) Releases FY20 Earnings Guidance

Eli Lilly And Co (NYSE:LLY) updated its FY20 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of $7.20-$7.40 for the period, compared to the Thomson Reuters consensus estimate of $6.84. The company issued revenue guidance of $23.7-$24.2 billion, compared to the consensus revenue estimate of $23.94 billion.Eli Lilly And Co also updated its FY 2020
Pre-Market guidance to 7.20-7.40 EPS.

Eli Lilly And Co stock opened at $150.29 on Friday. Eli Lilly And Co has a 52-week low of $101.36 and a 52-week high of $170.75. The company has a market cap of $143.74 billion, a price-to-earnings ratio of 24.40, a PEG ratio of 1.34 and a beta of 0.26. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 4.37. The firm’s fifty day moving average is $160.88 and its 200 day moving average is $148.62.

Eli Lilly And Co (NYSE:LLY) last announced its earnings results on Thursday, July 30th. The company reported $1.89 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.60 by $0.29. Eli Lilly And Co had a net margin of 24.48% and a return on equity of 200.78%. The business had revenue of $5.50 billion for the quarter, compared to the consensus estimate of $5.77 billion. During the same quarter in the prior year, the firm posted $1.50 earnings per share. The business’s revenue for the quarter was down 2.4% on a year-over-year basis. On average, equities research analysts anticipate that Eli Lilly And Co will post 7.3 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be paid a $0.74 dividend. This represents a $2.96 annualized dividend and a dividend yield of 1.97%. The ex-dividend date of this dividend is Thursday, August 13th. Eli Lilly And Co’s dividend payout ratio is currently 49.01%.

Several research analysts recently commented on LLY shares. JPMorgan Chase & Co. raised their price target on shares of Eli Lilly And Co from $175.00 to $190.00 and gave the stock an overweight rating in a research note on Wednesday, June 17th. Cowen raised their price target on shares of Eli Lilly And Co from $145.00 to $160.00 and gave the stock an outperform rating in a research note on Wednesday, April 15th. Morgan Stanley downgraded shares of Eli Lilly And Co from an overweight rating to an equal weight rating in a research note on Sunday, April 19th. Cfra raised their price target on shares of Eli Lilly And Co from $146.00 to $167.00 and gave the stock a hold rating in a research note on Friday, April 24th. Finally, Cantor Fitzgerald raised their price target on shares of Eli Lilly And Co from $156.00 to $185.00 and gave the stock an overweight rating in a research note on Friday, April 24th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of Buy and a consensus target price of $168.58.

In other news, major shareholder Lilly Endowment Inc sold 53,770 shares of the firm’s stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $161.54, for a total value of $8,686,005.80. Following the sale, the insider now directly owns 111,798,270 shares in the company, valued at approximately $18,059,892,535.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Alfonso G. Zulueta sold 17,000 shares of the firm’s stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $162.94, for a total transaction of $2,769,980.00. Following the completion of the sale, the senior vice president now owns 39,646 shares in the company, valued at $6,459,919.24. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 555,236 shares of company stock worth $91,393,391. 0.09% of the stock is owned by company insiders.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Read More: What is a dead cat bounce?

Earnings History and Estimates for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.